Drug intelligence / Profile preview

CP902

Development stage: Preclinical
Lead developer: Consegna Pharma
Modality: Peptides
Administration: Intramuscular

Overview

CP902 is a long-acting injectable formulation of octreotide, developed by Consegna Pharma as a generic version of Sandostatin LAR. It is designed as a 28-day release depot for the treatment of acromegaly and symptoms associated with carcinoid tumors. As a somatostatin receptor agonist, octreotide suppresses the secretion of growth hormone and various other peptide hormones. The program is being developed via the Abbreviated New Drug Application (ANDA) regulatory pathway and is currently in the preclinical stage.

Other names: octreotideSandostatin LAR generic

Targets

SSTR (Somatostatin receptors)

Beyond the preview

Go deeper on CP902.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP902.

Explore the full profile